DD274562A5 - Verfahren zur herstellung von pharmazeutischen zubereitungen - Google Patents

Verfahren zur herstellung von pharmazeutischen zubereitungen Download PDF

Info

Publication number: DD274562A5
Authority: DD; German Democratic Republic
Prior art keywords: pharmaceutical preparations; emulsion; prepared; contain; hydrogel
Prior art date: 1987-09-17

Application number

DD88319876A

Other languages

German (de)

English (en)

Inventor

Traute Mundorf

Kurt Schnecker

Original Assignee

��@��@��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-17

Filing date

1988-09-16

Publication date

1989-12-27

1988-09-16 Application filed by ��@��@��@��k�� filed Critical ��@��@��@��k��

1989-12-27 Publication of DD274562A5 publication Critical patent/DD274562A5/de

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 31
238000004519 manufacturing process Methods 0.000 title description 6
239000000839 emulsion Substances 0.000 claims abstract description 35
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 29
238000000034 method Methods 0.000 claims abstract description 27
238000002360 preparation method Methods 0.000 claims abstract description 22
230000008569 process Effects 0.000 claims abstract description 15
239000003381 stabilizer Substances 0.000 claims abstract description 15
239000003995 emulsifying agent Substances 0.000 claims abstract description 11
230000000699 topical effect Effects 0.000 claims abstract description 8
239000012071 phase Substances 0.000 claims abstract description 5
235000021120 animal protein Nutrition 0.000 claims abstract description 3
239000008346 aqueous phase Substances 0.000 claims abstract description 3
235000018102 proteins Nutrition 0.000 claims description 35
102000004169 proteins and genes Human genes 0.000 claims description 35
108090000623 proteins and genes Proteins 0.000 claims description 35
239000000017 hydrogel Substances 0.000 claims description 33
239000000126 substance Substances 0.000 claims description 30
239000005662 Paraffin oil Substances 0.000 claims description 22
230000002209 hydrophobic effect Effects 0.000 claims description 21
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 19
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 19
239000000203 mixture Substances 0.000 claims description 13
108010050904 Interferons Proteins 0.000 claims description 9
102000014150 Interferons Human genes 0.000 claims description 9
239000003921 oil Substances 0.000 claims description 9
230000006641 stabilisation Effects 0.000 claims description 9
238000011105 stabilization Methods 0.000 claims description 9
238000003756 stirring Methods 0.000 claims description 9
239000000654 additive Substances 0.000 claims description 8
238000009826 distribution Methods 0.000 claims description 8
229940047124 interferons Drugs 0.000 claims description 8
-1 TNFß Proteins 0.000 claims description 7
239000007853 buffer solution Substances 0.000 claims description 7
230000000694 effects Effects 0.000 claims description 7
108010010803 Gelatin Proteins 0.000 claims description 6
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
239000008273 gelatin Substances 0.000 claims description 6
229920000159 gelatin Polymers 0.000 claims description 6
235000019322 gelatine Nutrition 0.000 claims description 6
235000011852 gelatine desserts Nutrition 0.000 claims description 6
239000012188 paraffin wax Substances 0.000 claims description 5
239000003755 preservative agent Substances 0.000 claims description 5
230000002335 preservative effect Effects 0.000 claims description 4
239000000969 carrier Substances 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 2
239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
229960000686 benzalkonium chloride Drugs 0.000 claims description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
230000000975 bioactive effect Effects 0.000 claims description 2
229920002678 cellulose Polymers 0.000 claims description 2
239000001913 cellulose Substances 0.000 claims description 2
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 2
239000003906 humectant Substances 0.000 claims description 2
229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
239000012460 protein solution Substances 0.000 claims description 2
235000010199 sorbic acid Nutrition 0.000 claims description 2
239000004334 sorbic acid Substances 0.000 claims description 2
229940075582 sorbic acid Drugs 0.000 claims description 2
229920001059 synthetic polymer Polymers 0.000 claims description 2
229940090248 4-hydroxybenzoic acid Drugs 0.000 claims 1
108700012920 TNF Proteins 0.000 claims 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
238000004062 sedimentation Methods 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 abstract description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 34
239000000499 gel Substances 0.000 description 20
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 17
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 17
229960002216 methylparaben Drugs 0.000 description 17
229920001213 Polysorbate 20 Polymers 0.000 description 11
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 10
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 10
229940068977 polysorbate 20 Drugs 0.000 description 10
HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 10
BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
XQGPKZUNMMFTAL-UHFFFAOYSA-L dipotassium;hydrogen phosphate;trihydrate Chemical compound O.O.O.[K+].[K+].OP([O-])([O-])=O XQGPKZUNMMFTAL-UHFFFAOYSA-L 0.000 description 8
230000000087 stabilizing effect Effects 0.000 description 7
239000000243 solution Substances 0.000 description 6
239000000872 buffer Substances 0.000 description 5
238000009472 formulation Methods 0.000 description 5
229940043348 myristyl alcohol Drugs 0.000 description 5
239000002253 acid Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000002674 ointment Substances 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000013543 active substance Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000003860 storage Methods 0.000 description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 3
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
MTVWFVDWRVYDOR-UHFFFAOYSA-N 3,4-Dihydroxyphenylglycol Chemical compound OCC(O)C1=CC=C(O)C(O)=C1 MTVWFVDWRVYDOR-UHFFFAOYSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
102000008100 Human Serum Albumin Human genes 0.000 description 2
108091006905 Human Serum Albumin Proteins 0.000 description 2
102100037850 Interferon gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
102000016943 Muramidase Human genes 0.000 description 2
108010014251 Muramidase Proteins 0.000 description 2
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000008367 deionised water Substances 0.000 description 2
229910021641 deionized water Inorganic materials 0.000 description 2
238000010586 diagram Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
230000003993 interaction Effects 0.000 description 2
229940047122 interleukins Drugs 0.000 description 2
239000004325 lysozyme Substances 0.000 description 2
229960000274 lysozyme Drugs 0.000 description 2
235000010335 lysozyme Nutrition 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
235000021317 phosphate Nutrition 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229960004063 propylene glycol Drugs 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
150000005168 4-hydroxybenzoic acids Chemical class 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
HOOWCUZPEFNHDT-UHFFFAOYSA-N DHPG Natural products OC(=O)C(N)C1=CC(O)=CC(O)=C1 HOOWCUZPEFNHDT-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
102100026720 Interferon beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
108010074338 Lymphokines Proteins 0.000 description 1
102000008072 Lymphokines Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000013967 Monokines Human genes 0.000 description 1
108010050619 Monokines Proteins 0.000 description 1
241000233803 Nypa Species 0.000 description 1
235000005305 Nypa fruticans Nutrition 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000002506 anticoagulant protein Substances 0.000 description 1
239000004019 antithrombin Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036760 body temperature Effects 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
108010008429 immunoglobulin-binding factors Proteins 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical class CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
230000005501 phase interface Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000007420 reactivation Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
ZPOHATURJPDCDL-UHFFFAOYSA-N sodium dihydrogen phosphite hydrate Chemical compound O.[Na+].OP(O)[O-] ZPOHATURJPDCDL-UHFFFAOYSA-N 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
239000008362 succinate buffer Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
239000011885 synergistic combination Substances 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
150000004684 trihydrates Chemical class 0.000 description 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Inorganic Chemistry (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)

DD88319876A 1987-09-17 1988-09-16 Verfahren zur herstellung von pharmazeutischen zubereitungen DD274562A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19873731255 DE3731255A1 (de)	1987-09-17	1987-09-17	Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen

Publications (1)

Publication Number	Publication Date
DD274562A5 true DD274562A5 (de)	1989-12-27

Family

ID=6336244

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD88319876A DD274562A5 (de)	1987-09-17	1988-09-16	Verfahren zur herstellung von pharmazeutischen zubereitungen

Country Status (20)

Country	Link
EP (1)	EP0307857B1 (fr)
JP (1)	JP2783552B2 (fr)
KR (1)	KR970008112B1 (fr)
AT (1)	ATE126063T1 (fr)
AU (1)	AU615473B2 (fr)
CA (1)	CA1329121C (fr)
DD (1)	DD274562A5 (fr)
DE (2)	DE3731255A1 (fr)
DK (1)	DK516288A (fr)
ES (1)	ES2077559T3 (fr)
FI (1)	FI95770C (fr)
GR (1)	GR3017432T3 (fr)
HU (1)	HU203045B (fr)
IE (1)	IE70908B1 (fr)
IL (1)	IL87778A (fr)
NO (1)	NO179436C (fr)
NZ (1)	NZ226209A (fr)
PT (1)	PT88539B (fr)
RU (1)	RU2093145C1 (fr)
ZA (1)	ZA886903B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5332577A (en) *	1988-12-27	1994-07-26	Dermamed	Transdermal administration to humans and animals
US5241925A (en) *	1988-12-27	1993-09-07	Dermamed	Apparatus and techniques for administering veterinary medicaments
US5130298A (en) *	1989-05-16	1992-07-14	Ethicon, Inc.	Stabilized compositions containing epidermal growth factor
US5324521A (en) *	1989-12-18	1994-06-28	Dermamed	Systems for transdermal administration of medicaments
JPH0776527A (ja) *	1993-06-28	1995-03-20	Hayashibara Biochem Lab Inc	半固形製剤とその製造方法
RU2132184C1 (ru) *	1998-12-16	1999-06-27	Краснодарская научно-исследовательская ветеринарная станция	Способ получения препарата "жироформ-плюс" для лечения и профилактики эндометритов у коров
DK2153819T3 (da) *	2000-07-14	2012-12-03	Allergan Inc	Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
RU2216313C2 (ru) *	2000-12-25	2003-11-20	Савченков Сергей Николаевич	Лечебно-профилактическое косметическое средство
RU2188665C1 (ru) *	2001-04-09	2002-09-10	Щербакова Элеонора Григорьевна	Противовирусное и антибактериальное средство "интерлизин"
ITMI20031640A1 (it) *	2003-08-08	2005-02-09	Mipharm S P A	Base per gel bioadesivi.
CU23432B6 (es) *	2005-11-02	2009-10-16	Ct Ingenieria Genetica Biotech	Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
US9555120B2 (en)	2010-05-04	2017-01-31	Viscogel Ab	Chitosan composition
RU2431489C1 (ru) *	2010-05-25	2011-10-20	Федеральное государственное учреждение "Российский научный центр рентгенорадиологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "РНЦРР Росмедтехнологий")	Способ лечения хронических воспалительных заболеваний толстого кишечника
KR20260035292A (ko) *	2017-06-12	2026-03-12	레이크우드 아메덱스, 인크.	비스포스포신 겔 제제 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5413223A (en) *	1977-07-01	1979-01-31	Ricoh Co Ltd	Printer unit
GB2016015B (en) *	1978-01-22	1982-05-06	Hayashibara Co	Method of preparing interferon and preparations containing interferon
JPS5598118A (en) *	1979-01-18	1980-07-25	Hayashibara Takeshi	Preparation of type-2 interferon and drug containing the same
FR2513124B1 (fr) *	1981-07-21	1989-11-17	Hayashibara Biochem Lab	Production et applications du facteur de lyse des cellules-cibles
CA1190148A (fr) *	1981-10-13	1985-07-09	Samuel S. Asculai	Composes contenant de l'interferon
JPS5892622A (ja) *	1981-11-28	1983-06-02	Sunstar Inc	インタ−フエロン安定配合製剤
US4659696A (en) *	1982-04-30	1987-04-21	Takeda Chemical Industries, Ltd.	Pharmaceutical composition and its nasal or vaginal use
JPS5910524A (ja) *	1982-07-08	1984-01-20	Toray Ind Inc	インタ−フエロン組成物およびその製造法
JPS6061535A (ja) *	1983-08-24	1985-04-09	エフ・ホフマン・ラ・ロシユ・ウント・コンパニ−・アクチエンゲゼルシヤフト	製薬学的組成物
EP0177342A3 (fr) *	1984-10-04	1987-12-02	Genentech, Inc.	Formulations orales de protéines thérapeutiques
DE3603444A1 (de) *	1986-02-05	1987-08-06	Thomae Gmbh Dr K	Pharmazeutische zubereitungsformen zur stabilisierung von interferon alpha
US4822605A (en) *	1986-02-18	1989-04-18	Exovir, Inc.	Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like

1987
- 1987-09-17 DE DE19873731255 patent/DE3731255A1/de not_active Ceased
1988
- 1988-09-13 ES ES88114944T patent/ES2077559T3/es not_active Expired - Lifetime
- 1988-09-13 AT AT88114944T patent/ATE126063T1/de not_active IP Right Cessation
- 1988-09-13 EP EP88114944A patent/EP0307857B1/fr not_active Expired - Lifetime
- 1988-09-13 DE DE3854290T patent/DE3854290D1/de not_active Expired - Lifetime
- 1988-09-15 FI FI884240A patent/FI95770C/fi not_active IP Right Cessation
- 1988-09-16 HU HU884894A patent/HU203045B/hu unknown
- 1988-09-16 AU AU22316/88A patent/AU615473B2/en not_active Expired
- 1988-09-16 KR KR1019880011951A patent/KR970008112B1/ko not_active Expired - Lifetime
- 1988-09-16 IE IE281288A patent/IE70908B1/en not_active IP Right Cessation
- 1988-09-16 ZA ZA886903A patent/ZA886903B/xx unknown
- 1988-09-16 PT PT88539A patent/PT88539B/pt not_active IP Right Cessation
- 1988-09-16 DK DK516288A patent/DK516288A/da not_active Application Discontinuation
- 1988-09-16 IL IL87778A patent/IL87778A/xx active Protection Beyond IP Right Term
- 1988-09-16 JP JP63232113A patent/JP2783552B2/ja not_active Expired - Lifetime
- 1988-09-16 NZ NZ226209A patent/NZ226209A/en unknown
- 1988-09-16 CA CA000577614A patent/CA1329121C/fr not_active Expired - Lifetime
- 1988-09-16 DD DD88319876A patent/DD274562A5/de not_active IP Right Cessation
- 1988-09-16 NO NO884123A patent/NO179436C/no not_active IP Right Cessation
1992
- 1992-04-24 RU SU925011455A patent/RU2093145C1/ru active
1995
- 1995-09-18 GR GR950402557T patent/GR3017432T3/el unknown

Also Published As

Publication number	Publication date
KR970008112B1 (ko)	1997-05-21
NO179436C (no)	1996-10-09
ZA886903B (en)	1990-05-30
FI884240L (fi)	1989-03-18
IE70908B1 (en)	1997-01-15
FI884240A0 (fi)	1988-09-15
KR890004719A (ko)	1989-05-09
IL87778A (en)	1993-05-13
PT88539A (pt)	1988-10-01
DE3731255A1 (de)	1989-04-06
PT88539B (pt)	1992-11-30
NO884123L (no)	1989-03-20
NO179436B (no)	1996-07-01
CA1329121C (fr)	1994-05-03
DE3854290D1 (de)	1995-09-14
JP2783552B2 (ja)	1998-08-06
EP0307857A1 (fr)	1989-03-22
ES2077559T3 (es)	1995-12-01
HU203045B (en)	1991-05-28
AU615473B2 (en)	1991-10-03
IE882812L (en)	1989-03-17
ATE126063T1 (de)	1995-08-15
GR3017432T3 (en)	1995-12-31
IL87778A0 (en)	1989-03-31
JPH01102029A (ja)	1989-04-19
FI95770B (fi)	1995-12-15
AU2231688A (en)	1989-03-23
DK516288D0 (da)	1988-09-16
DK516288A (da)	1989-03-18
NO884123D0 (no)	1988-09-16
NZ226209A (en)	1991-06-25
EP0307857B1 (fr)	1995-08-09
RU2093145C1 (ru)	1997-10-20
HUT47436A (en)	1989-03-28
FI95770C (fi)	1996-03-25

Legal Events

Date	Code	Title	Description
1997-07-03	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE3785054T2 (de)	1993-07-08	Stabile emulsionen von stark fluorierten, organischen verbindungen.
DE3782420T2 (de)	1993-03-11	Wachstumhormonzubereitungen mit verzoegerter wirkstoffabgabe fuer eine parenterale verabreichung und ihre verwendung.
DE3587479T2 (de)	1993-12-09	Vehikel zur Verabreichung von Interferon.
DE69334134T2 (de)	2007-12-20	Wässrige Formulierung enthaltend Menschliches Wachstumshormon
DE3853191T2 (de)	1995-10-19	Arzneimittelträger.
DD274562A5 (de)	1989-12-27	Verfahren zur herstellung von pharmazeutischen zubereitungen
DE68907066T2 (de)	1993-12-16	Verbesserte Formulierungen mit kontrollierter Abgabe.
DE69837664T2 (de)	2008-01-03	Wässrige suspensionspräparationen mit exzellenter redispersibilität
DE2418345C2 (de)	1985-04-25	Pharmazeutisches Mittel für äußerliche Anwendung an menschlicher Haut
DE60027272T2 (de)	2007-01-25	Stabile, nichtwässrige, einphasige, biokompatible, viskose Träger und Formulierungen, die diese Träger verwenden
EP0231816B1 (fr)	1991-05-29	Préparations pharmaceutiques pour la stabilisation de l'interféron alpha
EP0456106B1 (fr)	1994-12-07	Emulsion stable pour l'administration pharmaceutique, procédé pour sa préparation et son emploi comme agent pharmaceutique
DE2834308A1 (de)	1979-02-15	Verfahren zur wasserabspaltung aus einer kolloidalen lipsomen-dispersion
DE68907312T2 (de)	1993-11-25	Bunazosin oder seine Salze enthaltende pharmazeutische Zubereitungen zur perkutanen Verabreichung.
DD298352A5 (de)	1992-02-20	Tretinoin enthaltende zubereitung und verfahren zu ihrer herstellung
DE1934334B2 (de)	1974-07-18	Wasserfreies Präparat auf Basis gesättigter Fettalkohole und Glykollösungsmittel
DD298053A5 (de)	1992-02-06	Verfahren zum herstellen einer stabilen zubereitung eines pharmazeutischen peptides
DE68907081T2 (de)	1993-10-21	Mittel mit erhöhtem Penetrationsvermögen.
DD203464A5 (de)	1983-10-26	Verfahren zur herstellung einer verbesserten oel-in-wasser-formulierung von 9-(2-hydroxy-aethoxymethyl)-guanin fuer lokale anwendung
DE2714065A1 (de)	1978-10-12	Instillationszubereitung
DE69019151T2 (de)	1996-01-25	Salbe enthaltend Deprodone proprionate.
DE3139519A1 (de)	1982-06-16	"topisch verabreichbare pharmazeutische zusammensetzungen, enthaltend anti-inflammatorische steroide"
EP1406658A1 (fr)	2004-04-14	Formulation liquide contenant le cetuximab et un ester d'acide gras de polyoxyethylensorbitane
DE1210127B (de)	1966-02-03	Verfahren zur Stabilisierung von lipophile Substanzen enthaltenden waessrigen Loesungen
DE4110779A1 (de)	1991-10-02	Liposomale formulierungen antimykotischer, antibakterieller und/oder antiphlogistischer arzneimittel fuer die lokale und vaginale anwendung